Emerging role of SIRT2 in non-small cell lung cancer (Review)
- Authors:
- Mengge Zheng
- Changyong Hu
- Meng Wu
- Yue Eugene Chin
-
Affiliations: Institute of Biology and Medical Sciences, Soochow University Medical College, Suzhou, Jiangsu 215123, P.R. China - Published online on: August 11, 2021 https://doi.org/10.3892/ol.2021.12992
- Article Number: 731
-
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Klar AJ, Fogel S and Macleod K: MAR1-a Regulator of the HMa and HMalpha Loci in Saccharomyces Cerevisiae. Genetics. 93:37–50. 1979. View Article : Google Scholar : PubMed/NCBI | |
|
Loo S and Rine J: Silencing and heritable domains of gene expression. Annu Rev Cell Dev Biol. 11:519–548. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Gottlieb S and Esposito RE: A new role for a yeast transcriptional silencer gene, SIR2, in regulation of recombination in ribosomal DNA. Cell. 56:771–776. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Guarente L: Diverse and dynamic functions of the Sir silencing complex. Nat Genet. 23:281–285. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tanny JC, Dowd GJ, Huang J, Hilz H and Moazed D: An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell. 99:735–745. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tanner KG, Landry J, Sternglanz R and Denu JM: Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci USA. 97:14178–14182. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hirschey MD: Old enzymes, new tricks: Sirtuins are NAD(+)-dependent de-acylases. Cell Metab. 14:718–719. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos GD, Karow M, Blander G, et al: SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 126:941–954. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J. 370((Pt 3)): 737–749. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Feldman JL, Dittenhafer-Reed KE, Kudo N, Thelen JN, Ito A, Yoshida M and Denu JM: Kinetic and structural basis for acyl-group selectivity and NAD(+) dependence in sirtuin-catalyzed deacylation. Biochemistry. 54:3037–3050. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L, Chopra V, Hersch SM and Kazantsev AG: The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum Mol Genet. 20:3986–3996. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rack JG, VanLinden MR, Lutter T, Aasland R and Ziegler M: Constitutive nuclear localization of an alternatively spliced sirtuin-2 isoform. J Mol Biol. 426:1677–1691. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo N, Ito A, Arata M, Nakata A and Yoshida M: Identification of a novel small molecule that inhibits deacetylase but not defatty-acylase reaction catalysed by SIRT2. Philos Trans R Soc Lond B Biol Sci. 373:201700702018. View Article : Google Scholar : PubMed/NCBI | |
|
Mei Z, Zhang X, Yi J, Huang J, He J and Tao Y: Sirtuins in metabolism, DNA repair and cancer. J Exp Clin Cancer Res. 35:1822016. View Article : Google Scholar : PubMed/NCBI | |
|
North BJ and Verdin E: Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One. 2:e7842007. View Article : Google Scholar : PubMed/NCBI | |
|
Mathias RA, Greco TM, Oberstein A, Budayeva HG, Chakrabarti R, Rowland EA, Kang Y, Shenk T and Cristea IM: Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell. 159:1615–1625. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tong Z, Wang M, Wang Y, Kim DD, Grenier JK, Cao J, Sadhukhan S, Hao Q and Lin H: SIRT7 Is an RNA-activated protein lysine deacylase. ACS Chem Biol. 12:300–310. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Eskandarian HA, Impens F, Nahori MA, Soubigou G, Coppée JY, Cossart P and Hamon MA: A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection. Science. 341:12388582013. View Article : Google Scholar : PubMed/NCBI | |
|
Cha Y, Han MJ, Cha HJ, Zoldan J, Burkart A, Jung JH, Jang Y, Kim CH, Jeong HC, Kim BG, et al: Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. Nat Cell Biol. 19:445–456. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, et al: SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents. Cancer Res. 76:5467–5478. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rothgiesser KM, Erener S, Waibel S, Lüscher B and Hottiger MO: SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci. (123)((Pt 24)): 4251–4258. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tsusaka T, Guo T, Yagura T, Inoue T, Yokode M, Inagaki N and Kondoh H: Deacetylation of phosphoglycerate mutase in its distinct central region by SIRT2 down-regulates its enzymatic activity. Genes Cells. 19:766–777. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sarikhani M, Mishra S, Desingu PA, Kotyada C, Wolfgeher D, Gupta MP, Singh M and Sundaresan NR: SIRT2 regulates oxidative stress-induced cell death through deacetylation of c-Jun NH2-terminal kinase. Cell Death Differ. 25:1638–1656. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fabrizio P, Gattazzo C, Battistella L, Wei M, Cheng C, McGrew K and Longo VD: Sir2 blocks extreme life-span extension. Cell. 123:655–667. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Horio Y, Hayashi T, Kuno A and Kunimoto R: Cellular and molecular effects of sirtuins in health and disease. Clin Sci (Lond). 121:191–203. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Michan S and Sinclair D: Sirtuins in mammals: Insights into their biological function. Biochem J. 404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
North BJ, Rosenberg MA, Jeganathan KB, Hafner AV, Michan S, Dai J, Baker DJ, Cen Y, Wu LE, Sauve AA, et al: SIRT2 induces the checkpoint kinase BubR1 to increase lifespan. EMBO J. 33:1438–1453. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dryden SC, Nahhas FA, Nowak JE, Goustin AS and Tainsky MA: Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol. 23:3173–3185. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW, Serrano L, Sternglanz R and Reinberg D: SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 20:1256–1261. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Serrano L, Martínez-Redondo P, Marazuela-Duque A, Vazquez BN, Dooley SJ, Voigt P, Beck DB, Kane-Goldsmith N, Tong Q, Rabanal RM, et al: The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev. 27:639–653. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, et al: SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 20:487–499. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G, Luo Y, Warncke K, Sun Y, Yu DS, Fu H, Behera M, Ramalingam SS, Doetsch PW, Duong DM, et al: Acetylation regulates ribonucleotide reductase activity and cancer cell growth. Nat Commun. 10:32132019. View Article : Google Scholar : PubMed/NCBI | |
|
Gonfloni S, Iannizzotto V, Maiani E, Bellusci G, Ciccone S and Diederich M: P53 and Sirt1: Routes of metabolism and genome stability. Biochem Pharmacol. 92:149–156. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cha YI and Kim HS: Emerging role of sirtuins on tumorigenesis: Possible link between aging and cancer. BMB Rep. 46:429–438. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Zhang M, Dorfman RG, Pan Y, Tang D, Xu L, Zhao Z, Zhou Q, Zhou L, Wang Y, et al: SIRT2 promotes the migration and invasion of gastric cancer through RAS/ERK/JNK/MMP-9 pathway by increasing PEPCK1-Related metabolism. Neoplasia. 20:745–756. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Park SH, Ozden O, Liu G, Song HY, Zhu Y, Yan Y, Zou X, Kang HJ, Jiang H, Principe DR, et al: SIRT2-Mediated deacetylation and tetramerization of pyruvate kinase directs glycolysis and tumor growth. Cancer Res. 76:3802–3812. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YP, Zhou LS, Zhao YZ, Wang SW, Chen LL, Liu LX, Ling ZQ, Hu FJ, Sun YP, Zhang JY, et al: Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. 33:1304–1320. 2014.PubMed/NCBI | |
|
Hamaidi I, Zhang L, Kim N, Wang MH, Iclozan C, Fang B, Liu M, Koomen JM, Berglund AE, Yoder SJ, et al: Sirt2 inhibition enhances metabolic fitness and effector functions of Tumor-Reactive T Cells. Cell Metab. 32:420–436.e412. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jing H, Zhang X, Wisner SA, Chen X, Spiegelman NA, Linder ME and Lin H: SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a. Elife. 6:e324362017. View Article : Google Scholar : PubMed/NCBI | |
|
Spiegelman NA, Zhang X, Jing H, Cao J, Kotliar IB, Aramsangtienchai P, Wang M, Tong Z, Rosch KM and Lin H: SIRT2 and Lysine fatty acylation regulate the activity of RalB and cell migration. ACS Chem Biol. 14:2014–2023. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kosciuk T, Price IR, Zhang X, Zhu C, Johnson KN, Zhang S, Halaby SL, Komaniecki GP, Yang M, DeHart CJ, et al: NMT1 and NMT2 are lysine myristoyltransferases regulating the ARF6 GTPase cycle. Nat Commun. 11:10672020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G, Huang P and Hu C: The role of SIRT2 in cancer: A novel therapeutic target. Int J Cancer. 147:3297–3304. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zhang Y, Zhu K, Chi S, Wang C and Xie A: Emerging role of Sirtuin 2 in Parkinson's disease. Front Aging Neurosci. 11:3722020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Anoopkumar-Dukie S, Arora D and Davey AK: Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases. Eur J Pharmacol. 867:1728472020. View Article : Google Scholar : PubMed/NCBI | |
|
Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W and Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 145:1175–1190. 1994.PubMed/NCBI | |
|
Head PE, Zhang H, Bastien AJ, Koyen AE, Withers AE, Daddacha WB, Cheng X and Yu DS: Sirtuin 2 mutations in human cancers impair its function in genome maintenance. J Biol Chem. 292:9919–9931. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Ye Y, Yang X, Liu B, Wang Z, Chen S, Jiang K, Zhang W, Jiang H, Mustonen H, et al: SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases. EMBO Rep. 21:e481832020. View Article : Google Scholar : PubMed/NCBI | |
|
Carafa V, Altucci L and Nebbioso A: Dual tumor suppressor and tumor promoter action of sirtuins in determining malignant phenotype. Front Pharmacol. 10:382019. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Xie QR, Chen Z, Lu S and Xia W: Regulation of SIRT2 levels for human non-small cell lung cancer therapy. Lung Cancer. 82:9–15. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio R and Montuenga LM: Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One. 10:e01246702015. View Article : Google Scholar : PubMed/NCBI | |
|
Gao CX, Chen B, Xie HK, Han CN and Luo J: Immunohistochemistry and clinical value of sirtuin 2 in non-metastasized non-small cell lung cancer. J Thorac Dis. 11:3973–3979. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
McGlynn LM, Zino S, MacDonald AI, Curle J, Reilly JE, Mohammed ZM, McMillan DC, Mallon E, Payne AP, Edwards J and Shiels PG: SIRT2: Tumour suppressor or tumour promoter in operable breast cancer? Eur J Cancer. 50:290–301. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gong J, Wang H, Lou W, Wang G, Tao H, Wen H, Liu Y and Xie Q: Associations of sirtuins with clinicopathological parameters and prognosis in non-small cell lung cancer. Cancer Manag Res. 10:3341–3356. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Berggrund M, Enroth S, Lundberg M, Assarsson E, Stålberg K, Lindquist D, Hallmans G, Grankvist K, Olovsson M and Gyllensten U: Identification of candidate plasma protein biomarkers for cervical cancer using the multiplex proximity extension assay. Mol Cell Proteomics. 18:735–743. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue K, Mallakin A and Frazier DP: Dmp1 and tumor suppression. Oncogene. 26:4329–4335. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Das C, Lucia MS, Hansen KC and Tyler JK: CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature. 459:113–117. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, Yeo CY and Lee KY: Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun. 368:690–695. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao D, Zou SW, Liu Y, Zhou X, Mo Y, Wang P, Xu YH, Dong B, Xiong Y, Lei QY and Guan KL: Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell. 23:464–476. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jing H, Hu J, He B, Negrón Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, et al: A SIRT2-Selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity. Cancer Cell. 29:6072016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang MH, Laurent G, Bause AS, Spang R, German N, Haigis MC and Haigis KM: HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol Cancer Res. 11:1072–1077. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Spiegelman NA, Hong JY, Hu J, Jing H, Wang M, Price IR, Cao J, Yang M, Zhang X and Lin H: A Small-Molecule SIRT2 inhibitor that promotes K-Ras4a lysine fatty-acylation. ChemMedChem. 14:744–748. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, et al: The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 20:503–514. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Luo J, Bao YC, Ji XX, Chen B, Deng QF and Zhou SW: SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth. Biochem Biophys Res Commun. 483:880–884. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Li F, Lv L, Li T, Zhou X, Deng CX, Guan KL, Lei QY and Xiong Y: Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res. 74:3630–3642. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, Wang D, Feng J, Yu L and Zhu WG: Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol. 12:665–675. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tang HX, Wang MY, Xiao W and Wen JW: SIRT2-Reverses Drug-Resistance of HL-60/A through autophagy mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 27:409–414. 2019.(In Chinese). PubMed/NCBI | |
|
Liu L, Yu L, Zeng C, Long H, Duan G, Yin G, Dai X and Lin Z: E3 Ubiquitin Ligase HRD1 promotes lung tumorigenesis by promoting sirtuin 2 ubiquitination and degradation. Mol Cell Biol. 40:e00257–19. 2020. View Article : Google Scholar | |
|
Zhu H, Hu Y, Zeng C, Chang L, Ge F, Wang W, Yan F, Zhao Q, Cao J, Ying M, et al: The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-small cell lung cancer. Theranostics. 10:2188–2200. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lin R, Tao R, Gao X, Li T, Zhou X, Guan KL, Xiong Y and Lei QY: Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell. 51:506–518. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mu N, Lei Y, Wang Y, Wang Y, Duan Q, Ma G, Liu X and Su L: Inhibition of SIRT1/2 upregulates HSPA5 acetylation and induces pro-survival autophagy via ATF4-DDIT4-mTORC1 axis in human lung cancer cells. Apoptosis. 24:798–811. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Xu P, Xie X, Hu F, Jiang L, Hu R, Ding F, Xiao H and Zhang H: Down regulation of SIRT2 Reduced ASS induced NSCLC apoptosis through the release of autophagy components via exosomes. Front Cell Dev Biol. 8:6019532020. View Article : Google Scholar : PubMed/NCBI | |
|
Bajpe PK, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R and Bernards R: A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene. 34:531–536. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xu H, Li Y, Chen L, Wang C, Wang Q, Zhang H, Lin Y, Li Q and Pang T: SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway. Int J Oncol. 48:613–623. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Du W, Acklin S, Jin S and Xia F: SIRT2 protects peripheral neurons from cisplatin-induced injury by enhancing nucleotide excision repair. J Clin Invest. 130:2953–2965. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao D, Mo Y, Li MT, Zou SW, Cheng ZL, Sun YP, Xiong Y, Guan KL and Lei QY: NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J Clin Invest. 124:5453–5465. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wei R, He D and Zhang X: Role of SIRT2 in regulation of stemness of cancer stem-like cells in renal cell carcinoma. Cell Physiol Biochem. 49:2348–2357. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Eramo A, Haas TL and De Maria R: Lung cancer stem cells: Tools and targets to fight lung cancer. Oncogene. 29:4625–4635. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA and Katz RL: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rotili D, Tarantino D, Nebbioso A, Paolini C, Huidobro C, Lara E, Mellini P, Lenoci A, Pezzi R, Botta G, et al: Discovery of salermide-related sirtuin inhibitors: Binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem. 55:10937–10947. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hu F, Sun X, Li G, Wu Q, Chen Y, Yang X, Luo X, Hu J and Wang G: Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3/VEGFA signalling pathway. Cell Death Dis. 10:92018. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffmann G, Breitenbücher F, Schuler M and Ehrenhofer-Murray AE: A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem. 289:5208–5216. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ma W, Zhao X, Wang K, Liu J and Huang G: Dichloroacetic acid (DCA) synergizes with the SIRT2 inhibitor Sirtinol and AGK2 to enhance anti-tumor efficacy in non-small cell lung cancer. Cancer Biol Ther. 19:835–846. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lima RT, Barron GA, Grabowska JA, Bermano G, Kaur S, Roy N, Vasconcelos MH and Lin PK: Cytotoxicity and cell death mechanisms induced by a novel bisnaphthalimidopropyl derivative against the NCI-H460 non-small lung cancer cell line. Anticancer Agents Med Chem. 13:414–421. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu G, Su L, Hao X, Zhong N, Zhong D, Singhal S and Liu X: Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med. 16:1618–1628. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Meissner F, Scheltema RA, Mollenkopf HJ and Mann M: Direct proteomic quantification of the secretome of activated immune cells. Science. 340:475–478. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lundby A, Lage K, Weinert BT, Bekker-Jensen DB, Secher A, Skovgaard T, Kelstrup CD, Dmytriyev A, Choudhary C, Lundby C and Olsen JV: Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep. 2:419–431. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Simon GM, Cheng J and Gordon JI: Quantitative assessment of the impact of the gut microbiota on lysine epsilon-acetylation of host proteins using gnotobiotic mice. Proc Natl Acad Sci USA. 109:11133–11138. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV and Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 325:834–840. 2009. View Article : Google Scholar : PubMed/NCBI |
